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mproving the
utcome of Childhood
ulmonary Arterial Hypertension
he Effect of Bosentan
n the Setting of a Dedicated
ulmonary Hypertension Clinic*
an Adatia, MBCHB
an Francisco, California
ulmonary arterial hypertension during childhood is a
eterogeneous disease that appears to have a genetic basis,
nd mutations involving bone morphogenetic protein recep-
or 2, activin receptor-like kinase 1, endoglin, and trans-
orming growth factor beta receptors have been documented
1–4). However, the rationale that underlies the use of
rugs to treat pulmonary vascular disease has resulted from
bservations that mediators of vasodilation and constriction,
s well as platelet, endothelial, and smooth muscle cell
ctivity, influence vascular remodeling. The L-arginine
itric oxide cyclic guanosine monophosphate and the pros-
acyclin cyclic adenosine monophosphate pathways are re-
See page 697
arded as beneficial. They promote vasodilation, decrease
latelet activation, and attenuate smooth muscle prolifera-
ion. The generally opposite and undesirable effects of
ndothelin and thromboxane counter these effects. Until
ecently, treatment with continuous intravenous prostacy-
lin was the only medical treatment for severe unreactive
ulmonary hypertension. It is an extraordinarily challenging
herapy for the family and child to embark upon, with
ainful side effects and serious complications. Newer drugs
hat can be administered orally or by inhalation have
articular relevance to the treatment of small children.
hese therapies include aerosolized iloprost, inhaled nitric
xide, and sildenafil, as well as combination therapy.
Pulmonary arterial hypertension is a relentlessly progres-
ive disease, and because inevitable patient attrition may
bscure benefits of new therapies, most trials have focused
n demonstrating functional benefit at 6 to 12 weeks. The
ong-term impact of therapy on disease is less secure, and
ttrition at one, three, and five years remains substantial (5).
s a prelude to the current study, a 12-week open-label
*Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
From the Department of Pediatrics, University of California San Franciscot
hildren’s Hospital, San Francisco, California. Dr. Adatia has been an advisor on
hildhood pulmonary hypertension to Pfizer, Actelion, and Wellcome.tudy of the pharmacokinetics of bosentan in children
emonstrated that bosentan was safe, could be dosed ap-
ropriately, and resulted in generally beneficial effects in
hildren over the short term (6). In this issue of the Journal,
osenzweig et al. (7) have reported a retrospective review of
he longer term effects of bosentan, an orally administered
ndothelin A and B receptor antagonist, in 86 children with
eterogeneous pulmonary arterial hypertension. The pri-
ary end point of therapy was the change in World Health
rganization (WHO) functional class. In patients treated
ith bosentan, WHO functional class improved in 46% and
emained unchanged in 44%. In an inevitably progressive
isease, like pulmonary arterial hypertension, unchanged
HO functional status suggests important prevention of
eterioration. In 49 children, modest but significant hemo-
ynamic improvement was demonstrated at serial cardiac
atheterization. Figure 3 of Rosenzweig et al. (7) is the most
elling and, at one year, of 32 patients treated with bosentan
lone, 3% had died, 9% had discontinued bosentan, and
2% received additional therapy. Similarly, of 32 patients
reated with prostanoids and bosentan, 3% died and 13%
iscontinued bosentan. At two years, there was an impres-
ive survival of 91% for all causes of pulmonary arterial
ypertension (with 88% survival for primary pulmonary
rterial hypertension and 96% for secondary pulmonary
rterial hypertension).
There is a dearth of information to guide the therapy of
hildhood disease, and the report by Rosenzweig et al. (7) is
mportant, not only because it provides guidance on the use
f a drug specifically in childhood disease, but also because
t highlights the many difficulties faced by investigators of
reatments for rare and chronic childhood illness. Although
y definition the diagnosis of pulmonary arterial hyperten-
ion requires documentation of an elevated pulmonary
rtery pressure, it is clear that patients’ symptoms and
urvival depend much more on right ventricular perfor-
ance and the ability of the right ventricle to compensate
or the increased afterload (8,9). However, cardiopulmo-
ary testing with measurement of maximal oxygen con-
umption or tests of distance walked in 6 min are almost
mpossible to perform in children younger than five to
even years of age.
In addition, the results of such tests are more easily
onfounded in children and adolescents by the vagaries
mposed by a change in routine. These include an early start
o the day with a long journey to the clinic and inevitable
nterruption of eating and sleep schedules. Thus, Rosen-
weig et al. (7) have chosen to follow a functional surrogate,
escribed by the change in WHO class with therapy. This
pproach has merit because the final arbiter of therapy, from
patient’s point of view, is not hemodynamic but improve-
ent in lifestyle. However, the need is obvious for validated
uality-of-life questionnaires and easily accomplished re-
roducible tests of functional ability or surrogates thereof
hat span the age from infancy to adolescence. Children
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Editorial Comment August 16 2005:705–6ompensate for disability remarkably, and often it is only
ith hindsight that even parents recognize the degree of
imitation present before an intervention, such as, for
xample, correction of congenital heart disease.
There was no control group in this study. Therefore,
ther factors could have contributed to the improved out-
omes. The care of children with pulmonary arterial hyper-
ension is challenging. The study originates from two
enters of excellence in childhood pulmonary hypertensive
isease. At both centers, there is an organized approach to
hildhood pulmonary hypertensive diseases with a dedicated
linic composed of experienced and skillful physicians,
urses, technicians, and support staff with established lines
f communication to patient and family support groups.
lthough the report by Rosenzweig et al. (7) focuses on the
se of bosentan, the importance of the environment in
hich it was administered should not be diminished.
enters with few patients and insufficient resources to
rovide all the benefits of a dedicated pulmonary hyperten-
ion clinic for children will not reproduce the results
eported by Rosenzweig et al. (7).
In summary, the report by Rosenzweig et al. (7) demon-
trates the effect of bosentan when administered in the
etting of a dedicated childhood pulmonary hypertension
ervice. The place of bosentan in the treatment of childhood
ulmonary hypertension, whether as single or combination
herapy, awaits further investigation. However, it highlights
lso the need for better and more specific tools with which
o assess the quality of life and functional outcome of
nterventions for childhood disease.eprint requests and correspondence: Dr. Ian Adatia, Depart-
ent of Pediatrics, University of California San Francisco Chil-
ren’s Hospital, San Francisco, California 94143-0106. E-mail:
adatia@pedcard.ucsf.edu.
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